Pembrolizumab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Pembrolizumab |
| DrugBank ID | DB09037 |
| Brand Names (EU) | Keytruda |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.40% |
Approved Indication (EMA)
Melanoma Keytruda as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma. Keytruda as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, IIC, or with Stage III melanoma and lymph node involvement who have undergone complete resection. Non small cell lung carcinoma (NSCLC) Keytruda, in combination with platinum-containing chemotherapy
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | fibromatosis, gingival | 99.40% | DL |
| 2 | inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia | 99.37% | DL |
| 3 | hamartoma of lung | 99.35% | DL |
| 4 | lung hilum carcinoma | 99.35% | DL |
| 5 | fibroma of lung | 99.34% | DL |
| 6 | lung benign neoplasm | 99.32% | DL |
| 7 | ovarioleukodystrophy | 99.32% | DL |
| 8 | pulmonary sulcus neoplasm | 99.29% | DL |
| 9 | lung germ cell tumor | 99.29% | DL |
| 10 | Leukomelanoderma-infantilism-intellectual disability-hypodontia-hypotrichosis syndrome | 99.28% | DL |
| 11 | junctional epidermolysis bullosa | 99.23% | DL |
| 12 | dehydratase deficiency | 99.18% | DL |
| 13 | lung cancer | 99.18% | DL |
| 14 | junctional epidermolysis bullosa, non-Herlitz type | 99.15% | DL |
| 15 | metastatic melanoma | 97.34% | DL |
| 16 | non-cutaneous melanoma | 97.04% | DL |
| 17 | epithelioid cell melanoma | 96.97% | DL |
| 18 | choroideremia | 96.88% | DL |
| 19 | eyelid melanoma | 96.83% | DL |
| 20 | CDK4 linked melanoma | 96.79% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.